News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
491,624 Results
Type
Article (8706)
Company Profile (142)
Press Release (482869)
Multimedia
Podcasts (6)
Webinars (6)
Section
Business (168281)
Career Advice (315)
Deals (25923)
Drug Delivery (10)
Drug Development (53906)
Employer Resources (15)
FDA (9998)
Job Trends (8717)
News (240973)
Policy (18142)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (536)
Accelerated approval (25)
ADA (21)
Adcomms (2)
Allergies (99)
Alliances (33624)
ALS (108)
Alzheimer's disease (1026)
Antibody-drug conjugate (ADC) (280)
Approvals (10631)
Artificial intelligence (362)
ASCO (170)
Autoimmune disease (221)
Automation (29)
Bankruptcy (263)
Best Places to Work (7092)
BIO (38)
Biologics (2)
BIOSECURE Act (1)
Biosimilars (115)
BioSpace Insights (25)
Biotechnology (88)
Bladder cancer (141)
Brain cancer (34)
Breast cancer (537)
Cancer (3868)
Cardiovascular disease (242)
Career advice (256)
Career pathing (2)
CAR-T (192)
Celiac Disease (1)
Cell therapy (516)
Cervical cancer (37)
Clinical research (48909)
Collaboration (1295)
Commercialization (3)
Compensation (1491)
Complete response letters (34)
COVID-19 (767)
CRISPR (66)
C-suite (790)
Cystic fibrosis (88)
Data (5943)
Denatured (5)
Depression (118)
Dermatology (64)
Diabetes (365)
Diagnostics (4256)
Digital health (41)
Diversity (1)
Diversity, equity & inclusion (5)
Drug discovery (174)
Drug pricing (10)
Drug shortages (3)
Duchenne muscular dystrophy (168)
Earnings (74110)
Editorial (2)
Employer branding (2)
Employer resources (15)
Events (88742)
Executive appointments (729)
FDA (12737)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (24)
Funding (1006)
Gene editing (135)
Generative AI (10)
Gene therapy (339)
GLP-1 (316)
Government (995)
Grass and pollen (2)
Guidances (288)
Healthcare (9549)
Hematology (103)
HIV (52)
Huntington's disease (24)
IgA nephropathy (67)
Immunology and inflammation (108)
Immuno-oncology (63)
Indications (163)
Infectious disease (958)
Inflammatory bowel disease (131)
Inflation Reduction Act (4)
Influenza (85)
Intellectual property (259)
Interviews (42)
IPO (12492)
IRA (3)
Job creations (1987)
Job search strategy (245)
JPM (3)
Kidney cancer (17)
Layoffs (60)
Legal (5219)
Licensing (10)
Liver cancer (44)
Longevity (19)
Lung cancer (530)
Lymphoma (273)
Machine learning (32)
Management (3)
Manufacturing (551)
Marketing (8)
MASH (121)
Medical device (8843)
Medtech (8995)
Mergers & acquisitions (14479)
Metabolic disorders (756)
mRNA (59)
Multiple sclerosis (111)
NASH (5)
Neurodegenerative disease (233)
Neuropsychiatric disorders (46)
Neuroscience (1939)
NextGen: Class of 2026 (3227)
Non-profit (913)
Obesity (245)
Opinion (25)
Ovarian cancer (167)
Pain (176)
Pancreatic cancer (208)
Parkinson's disease (212)
Partnered (14)
Patents (485)
Patient recruitment (545)
Peanut (31)
People (41797)
Pharmaceutical (30)
Pharmacy benefit managers (9)
Phase 1 (15745)
Phase 2 (21840)
Phase 3 (14793)
Pipeline (7619)
Policy (22)
Postmarket research (1586)
Preclinical (6658)
Press Release (34)
Prostate cancer (203)
Psychedelics (21)
Radiopharmaceuticals (201)
Rare diseases (603)
Real estate (3052)
Recruiting (6)
Regulatory (15149)
Reports (21)
Research institute (634)
Resumes & cover letters (45)
Rett syndrome (42)
RNA editing (6)
RSV (48)
Schizophrenia (105)
Series A (178)
Series B (139)
Service/supplier (6)
Sickle cell disease (65)
Spinal muscular atrophy (88)
Sponsored (6)
Startups (2099)
Stomach cancer (4)
Supply chain (50)
Tariffs (2)
Vaccines (335)
Venture capital (25)
Weight loss (83)
Women's health (83)
Date
Today (58)
Last 7 days (225)
Last 30 days (1676)
Last 365 days (19705)
2026 (12852)
2025 (19872)
2024 (23566)
2023 (27127)
2022 (35178)
2021 (37775)
2020 (33939)
2019 (23780)
2018 (17925)
2017 (19123)
2016 (18224)
2015 (24589)
2014 (21853)
2013 (18265)
2012 (20344)
2011 (20575)
2010 (20425)
Location
Africa (235)
Alabama (74)
Alaska (2)
Arizona (307)
Arkansas (11)
Asia (18441)
Australia (2197)
California (12248)
Canada (3193)
China (579)
Colorado (486)
Connecticut (414)
Delaware (222)
Europe (26687)
Florida (1819)
Georgia (387)
Hawaii (3)
Idaho (46)
Illinois (712)
India (53)
Indiana (318)
Iowa (15)
Japan (410)
Kansas (101)
Kentucky (31)
Louisiana (30)
Maine (26)
Maryland (1221)
Massachusetts (8023)
Michigan (309)
Minnesota (579)
Mississippi (4)
Missouri (82)
Montana (20)
Nebraska (11)
Nevada (119)
New Hampshire (61)
New Jersey (2687)
New Mexico (14)
New York (2895)
North Carolina (1311)
North Dakota (4)
Northern California (6145)
Ohio (282)
Oklahoma (14)
Oregon (19)
Pennsylvania (2284)
Puerto Rico (21)
Rhode Island (31)
South America (415)
South Carolina (76)
South Dakota (1)
Southern California (5075)
Tennessee (125)
Texas (1995)
United States (39698)
Utah (363)
Vermont (1)
Virginia (153)
Washington D.C. (38)
Washington State (949)
West Virginia (1)
Wisconsin (76)
Wyoming (1)
491,624 Results for "paradigm biodevices inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Insights
The next treatment-resistant depression paradigm
In this episode of Denatured, you’ll hear from Hans Eriksson, chief medical officer at FundaMental Pharma and Steve Levine, chief patient officer at Compass Pathways. We explore why treatment-resistant depression remains so difficult to address, and how new approaches—from rapid-acting antidepressants to psychedelic therapy—may reshape the treatment paradigm.
August 6, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Press Releases
Paradigm Clinical Research Opens Psychedelic Research Suite in Redding, California
New specialized treatment site expands Paradigm’s capabilities for psychiatric clinical trials and studies evaluating investigational psychedelic-assisted therapies
June 18, 2026
·
1 min read
Press Releases
Paradigm Clinical Research Appoints Greg Licholai, MD, to Board of Directors
Physician-executive with 30+ years across clinical practice, biotech, and digital health joins board to advance Paradigm’s mission and growth
June 10, 2026
·
1 min read
Press Releases
Novel Radiation Strategy Redefines a New Treatment Paradigm for Glioblastoma
August 18, 2026
·
6 min read
Press Releases
Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
June 8, 2026
·
4 min read
Press Releases
Paradigm Health Implements New Clinical Trial Solution to Support Observational Study Presented at ASCO
June 1, 2026
·
5 min read
Press Releases
Paradigm Health Announces Collaboration with the FDA to Transform Regulatory Review of Clinical Trial Data
April 29, 2026
·
4 min read
Press Releases
Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
June 2, 2026
·
12 min read
Press Releases
Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial
May 5, 2026
·
4 min read
Press Releases
Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial
April 28, 2026
·
3 min read
1 of 49,163
Next
